GNI Group is strengthening its global expansion centered on the US and China, with the acquisition of Gyre Therapeutics scheduled for completion in Q2 2026. The R&D pipeline consists of 23 products, with 990 employees as of the end of December 2025.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/2160-20260331-01.pdf","jir_short_summary":"GNI Group is strengthening its global expansion centered on the US and China, with the acquisition of Gyre Therapeutics scheduled for completion in Q2 2026. The R&D pipeline consists of 23 products, with 990 employees as of the end of December 2025.","jir_summary":"### Overview of GNI Group and Global Expansion\nGNI Group is a global biopharmaceutical company headquartered in Japan, operating in China, the United States, and Australia. Its business is composed of three pillars: pharmaceuticals, drug discovery, and medical devices, focusing on key therapeutic areas including fibrosis, pain, oncology, and orthopedics. As of the end of December 2025, the company employs 990 personnel and consists of 26 group companies. The R&D pipeline includes 23 products, with 3,000 hospital sales networks and 400 medical representatives in China.\n\n### Growth Strategy and Organizational Structure\nThe Group has established a healthcare value chain spanning Japan, China, the US, and Australia, achieving a global balance of innovation, efficiency, and agility. The acquisition of Gyre Therapeutics (United States) is scheduled for early Q2 2026, completing integration into the pharmaceutical business. Post-acquisition, the product and development portfolio will feature 10 disclosed programs focusing on inflammation, pain, and oncology. The organizational structure centers on President and CEO Mr. In Luo, with management teams in both the US and China working collaboratively. The medtech business will also be strengthened, and with the addition of ZOO LABO to the group, the number of employees in Japan is expected to expand to approximately 1,000.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#GNIGroup, #BusinessStrategy, #GlobalExpansion","jir_key_figures":"Number of employees: 990 (as of the end of December 2025)\nNumber of R&D pipeline products: 23\nScheduled completion date for Gyre Therapeutics acquisition: Early Q2 2026","jir_meta_title":"GNI Group's Global Growth Strategy and Scheduled Completion of Gyre Acquisition in Q2 2026","jir_meta_description":"GNI Group accelerates global expansion focusing on Japan, China, and the US. With 23 products in the R&D pipeline and 990 employees, the Gyre Therapeutics acquisition is set to complete in Q2 2026.","jir_og_title":"GNI Group's Global Growth Strategy and Gyre Acquisition Plan","jir_og_description":"GNI Group enhances global expansion with the Gyre acquisition scheduled for completion in Q2 2026. Maintains a pipeline of 23 R&D products and workforce of 990 employees.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-38312","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n